QbDVision, founded in 2016, has positioned itself as a pivotal player in the biotechnology and pharmaceutical sectors. Specializing as a Digital CMC Platform, they cater to manufacturing needs within the biotech and pharma industries, focusing on streamlining processes to expedite drug development.
With its headquarters in the United States, QbDVision leverages industry expertise to tackle existing challenges. Their platform is designed to enhance productivity and innovation, thus facilitating the swift delivery of breakthrough therapies.
The company completed a substantial Series A funding round on February 10, 2022, raising $15.00M. This funding was contributed by notable investors, including S3 Ventures, Northpond Ventures, Wanxiang Healthcare, and Hudson Park Capital. Such financial backing underscores investor confidence in QbDVision's potential to transform the pharmaceuticals manufacturing landscape.